{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041316","form_type":"8-K","ticker":"TKNO","cik":"0001850902","company_name":"Alpha Teknova, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.763202+00:00","generated_at":"2026-06-11T19:16:21.145058+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Teknova Q2 revenue $11.5M (+26% seq, -1% YoY); cuts 2023 revenue guidance to $37-40M","bullets":["Q2 revenue $11.5M, up 26% sequentially but down 1% YoY; net loss $7.2M ($0.25/share).","Clinical Solutions revenue grew 24% YoY to $3.7M; Lab Essentials fell 10% to $7.6M.","Company reduces 2023 revenue guidance to $37-40M from prior; maintains free cash outflow ~$30M.","Received certification for new GMP production facility, expanding capacity to $200M.","Adjusted EBITDA improved to -$2.3M from -$4.9M; non-cash impairment charge of $2.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041316","json":"https://secwatch.observer/filing/0000950170-23-041316.json","markdown":"https://secwatch.observer/filing/0000950170-23-041316.md","text":"https://secwatch.observer/filing/0000950170-23-041316.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850902/000095017023041316/0000950170-23-041316-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850902/000095017023041316/tkno-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T19:16:21.145058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"79527a9b6fb4d7f1080859e0a9d35f9dec8ccad1","claim":"Alpha Teknova, Inc. reported the second quarter ended June 30, 2023 results: revenue $11.5 million, EPS negative $0.25 per diluted share. Guidance lowered.","evidence_excerpt":"to be furnished under Item 2.02 and --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Teknova Reports Second Quarter 2023 Financial Results Second quarter 2023 total revenue was $11.5 million, up 26% sequentially Received certification of new state-of-the-art facility for production of GMP-grade products Company revises 2023 revenue guidance to $37-40 million,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850902/000095017023041316/0000950170-23-041316-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$11.5 million"},{"label":"EPS","value":"negative $0.25 per diluted share"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}